EA202091028A1 - Ароматические сульфонамидные производные для лечения ишемического инсульта - Google Patents

Ароматические сульфонамидные производные для лечения ишемического инсульта

Info

Publication number
EA202091028A1
EA202091028A1 EA202091028A EA202091028A EA202091028A1 EA 202091028 A1 EA202091028 A1 EA 202091028A1 EA 202091028 A EA202091028 A EA 202091028A EA 202091028 A EA202091028 A EA 202091028A EA 202091028 A1 EA202091028 A1 EA 202091028A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
ischemic stroke
sulfonamide derivatives
aromatic sulfonamide
tautomer
Prior art date
Application number
EA202091028A
Other languages
English (en)
Inventor
Петер Хауфф
Штефан Вернер
Original Assignee
Байер Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Акциенгезельшафт filed Critical Байер Акциенгезельшафт
Publication of EA202091028A1 publication Critical patent/EA202091028A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Соединение формулы (I)или N-оксид, соль, гидрат, сольват, таутомер или стереоизомер указанного соединения, или соль указанного N-оксида, таутомера или стереоизомера для применения для лечения или профилактики ишемии головного мозга, ишемической травмы головного мозга, ишемического инсульта (ИИ), геморрагического инсульта, черепно-мозговой травмы, повреждения спинного мозга.
EA202091028A 2017-10-29 2018-10-24 Ароматические сульфонамидные производные для лечения ишемического инсульта EA202091028A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17199070 2017-10-29
PCT/EP2018/079145 WO2019081573A1 (en) 2017-10-29 2018-10-24 AROMATIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF ISCHEMIC CEREBRAL ACCIDENTS

Publications (1)

Publication Number Publication Date
EA202091028A1 true EA202091028A1 (ru) 2020-09-09

Family

ID=60191221

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091028A EA202091028A1 (ru) 2017-10-29 2018-10-24 Ароматические сульфонамидные производные для лечения ишемического инсульта

Country Status (16)

Country Link
US (1) US20210179577A1 (ru)
EP (1) EP3700891A1 (ru)
JP (1) JP2021501178A (ru)
KR (1) KR20200081445A (ru)
CN (1) CN111511720A (ru)
AU (1) AU2018356430A1 (ru)
BR (1) BR112020008484A2 (ru)
CA (1) CA3079469A1 (ru)
CL (1) CL2020001139A1 (ru)
EA (1) EA202091028A1 (ru)
IL (1) IL274041A (ru)
JO (1) JOP20200077A1 (ru)
MA (1) MA50448A (ru)
MX (1) MX2020004472A (ru)
SG (1) SG11202003565PA (ru)
WO (1) WO2019081573A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102388962B1 (ko) * 2016-05-03 2022-04-27 바이엘 파마 악티엔게젤샤프트 방향족 술폰아미드 유도체
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CA3188308A1 (en) 2020-06-30 2022-01-06 Bayer Aktiengesellschaft Substituted n-phenylacetamides having p2x4 receptor antagonistic activity
WO2022049253A1 (en) 2020-09-07 2022-03-10 Bayer Aktiengesellschaft Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
CN116635020A (zh) * 2021-01-27 2023-08-22 武汉朗来科技发展有限公司 一种芳香化合物、其制备方法及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
HRP20211973T1 (hr) * 2009-09-03 2022-03-18 Bristol-Myers Squibb Company Kinazolini kao inhibitori ionskih kalijskih kanala
JP2013523658A (ja) 2010-03-26 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのピラゾリル‐ピリミジン
NZ604306A (en) 2010-05-17 2015-02-27 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
WO2015088565A1 (en) 2013-12-13 2015-06-18 Sunovion Pharmaceuticals Inc. P2x4 receptor modulating compounds and methods of use thereof
WO2015088564A1 (en) 2013-12-13 2015-06-18 Sunovion Pharmaceuticals Inc. P2x4 receptor modulating compounds
CA2988637A1 (en) * 2015-06-10 2016-12-15 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
KR102388962B1 (ko) * 2016-05-03 2022-04-27 바이엘 파마 악티엔게젤샤프트 방향족 술폰아미드 유도체

Also Published As

Publication number Publication date
CL2020001139A1 (es) 2020-10-23
JP2021501178A (ja) 2021-01-14
WO2019081573A1 (en) 2019-05-02
CA3079469A1 (en) 2019-05-02
WO2019081573A9 (en) 2020-05-28
MX2020004472A (es) 2020-08-06
EP3700891A1 (en) 2020-09-02
CN111511720A (zh) 2020-08-07
KR20200081445A (ko) 2020-07-07
IL274041A (en) 2020-06-30
SG11202003565PA (en) 2020-05-28
BR112020008484A2 (pt) 2020-10-20
US20210179577A1 (en) 2021-06-17
MA50448A (fr) 2020-09-02
AU2018356430A1 (en) 2020-04-30
JOP20200077A1 (ar) 2020-04-30

Similar Documents

Publication Publication Date Title
EA202091028A1 (ru) Ароматические сульфонамидные производные для лечения ишемического инсульта
CY1121938T1 (el) Αγωνιστες apj 4-υδροξυ-3-(ετερο¶ρυλ)πυριδινο-2-ονης για χρηση στη θεραπεια καρδιαγγειακων διαταραχων
EA202091506A1 (ru) Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa
MX2022011029A (es) Compuestos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos.
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
MX2020005323A (es) Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
EA201791882A1 (ru) Агонисты 5ht для лечения нарушений
TN2017000483A1 (en) Triazole agonists of the apj receptor.
EA201990833A1 (ru) Соединение пиридина
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
CY1121746T1 (el) Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης
AR103680A1 (es) Inhibidores selectivos de bace1
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
PH12017550004A1 (en) Heterocyclic derivatives and use thereof
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
HK1254393A1 (zh) 1-(5-(2，4-二氟苯基)-1-((3-氟苯基)磺酰基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺鹽新晶型
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
WO2019040104A3 (en) COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
BR112018015855A2 (pt) derivado de sulfonamida.